Nkarta, Inc.

Nkarta, Inc.

NKTXยทNASDAQ

$2.72

-1.8%
HealthcareBiotechnology

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$194.60M
EPS-1.4100
P/E Ratio-1.93
Earnings Date08/06/2026

No Dividend Yield Data

NKTX has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

NKTX has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

NKTX has not reported any net dividends paid values in the available annual periods.

Nkarta, Inc.

Nkarta, Inc. Dividend History

NKTX ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

NKTX Dividend Payment History

NKTX ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
nktx

Nkarta, Inc. Payout Ratio Analysis

NKTX ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-104.08M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.